Results 161 to 170 of about 92,477 (262)

Genomic and Transcriptomic Analysis of High-Grade Endometrial Carcinoma Reveals Biological Heterogeneity and Molecular Classification Challenges. [PDF]

open access: yesCancer Res Commun
Kawazu M   +22 more
europepmc   +1 more source

Exposure–Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial

open access: yesClinical Pharmacology in Drug Development, Volume 15, Issue 8, August 2026.
Abstract Dostarlimab in combination with carboplatin–paclitaxel was approved for primary advanced or recurrent endometrial cancer (pA/rEC). The first interim analysis (IA1) of RUBY Part 1 (NCT03981796) showed no significant exposure–response (ER) relationship for progression‐free survival or for the five most common dostarlimab‐related adverse events ...
Mita Kuchimanchi   +17 more
wiley   +1 more source

Identification of Prognostic Genes Relevant With the Nuclear Factors of Activated T Cells Based on Transcriptomics in Oral Squamous Cell Carcinoma

open access: yesClinical and Experimental Dental Research, Volume 12, Issue 4, August 2026.
ABSTRACT Background It has previously been demonstrated that the nuclear factor of activated T cells (NFAT) is crucial for the development of tumors. Given OSCC's drug resistance and poor outcomes, identifying NFAT‐associated prognostic genes is urgent for better treatment.
Julaiti Tuerxun   +2 more
wiley   +1 more source

Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report. [PDF]

open access: yesCancer Res Commun
Radulovich N   +15 more
europepmc   +1 more source

TCF/LEF family transcription factors: Molecular landscape and prognostic scoring in pan‐cancer

open access: yesClinical and Translational Discovery, Volume 6, Issue 4, August 2026.
This study provides a comprehensive molecular landscape of TCF/LEF family transcription factors across 33 cancer types. We developed a TCF/LEF‐based prognostic score that correlates with immune infiltration, metabolic reprogramming and drug sensitivity, offering a robust transcriptomic signature for predicting patient survival and therapeutic response.
Zhengjun Yang   +8 more
wiley   +1 more source

Urokinase Plasminogen Activator Receptor‐Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST)

open access: yesInternational Journal of Cancer, Volume 159, Issue 3, Page 797-808, 1 August 2026.
A key component of the collagen internalization and lysosomal degradation cellular machinery, uPARAP may contribute to cancer progression. Here, the authors explored the expression of uPARAP in gastrointestinal stromal tumors using well‐annotated clinical patient samples and specimens from cell line‐ and patient‐derived xenografts.
Chao‐Chi Wang   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy